Two new studies show, insight into genes that play a key role in disrupting immune system pathways in the brains of people with Alzheimer’s disease could offer a potential target for new drugs against the disease. If interested in the full article, click here….
Eli Lilly and Co. has acquired two investigational PET imaging agents from Siemens Healthcare in an effort to boost its commitment to Alzheimer’s disease research and development. Both tracers have been clinically proven to selectively target neurofibrillary tangles (NFTS), or tau, a diagnostic biomarker for Alzheimer’s disease. To read more of this article….
The Clarity technique ushers in a new era of brain imaging, offering hope for improving the study of such neurological disorders as autism, schizophrenia, Alzheimer’s disease and Parkinson’s disease. Read full article…
Researchers at the Linda Crnic Institute for Down Syndrome and the University of Colorado School of Medicine have found that a single mechanism may underlie the damaging effect of cholesterol on the brain and on blood vessels.
High levels of blood cholesterol increase the risk of both Alzheimer’s disease and heart disease. Read the full story…
The 2013-2014 Kroger Community Rewards Program begins May 1, 2013. All supporters of The Alois Alzheimer Foundation who registered prior to April 1, 2013 must re-enroll by April 30, 2013 online to continue supporting our organization.
Re-enrolling only takes a few moments and is completed in a few simple steps:
1. Visit our website at http://www.krogercommunityrewards.com
2. Sign in using your email address and password. If you have forgotten your password, just click on “forgot password” and a link will be sent to
your email to change your password.
3. Enter our organizations five digit NPO number (83519) or the first three letters of our organization’s name, click search.
4. Select The Alois Alzheimer Foundation by clicking on the circle to the left of our name.
5. Save changes
Thank you for your continued support of The Alois Alzheimer Foundation.